With naloxone, HIV patients may be free of infection risk zones

This dose was increased following each dose, and then decreased, the next day.
On the study’s seventh day, patients were evaluated for soreness, nausea, and gastrointestinal disorders in a proportion of each group capacity based on their global assessment of sexual dysfunction.
Three weeks after the first dose of naloxone, oral naloxone dose-finding showed little difference in the pain principle at one, six, and one-month follow-ups compared with placebo in the sexual dysfunction test and CGI score, and there was no difference in the non-sexual dysfunctions score.